Pregabalin enhances the proliferative potential of pancreatic cancer in vitro but not in mice with pancreatic cancer Authors: Tomoaki Itaya, Makoto Sano, Ichie Kajiwara, Yukino Oshima, Tomoya Kuramochi, Jinsuk Kim, Osamu Kitajima, Hideaki Ijichi, Takahiro Suzuki Published: 2026 ABSTRACT BackgroundWe previously reported that mirogabalin, a selective voltage-gated calcium channel α2δ1/α2δ2 ligand, increases the proliferative potential of pancreatic cancer. However, the risk of pregabalin, a non-selective α2δ ligand, is unknown in pancreatic cancer. Therefore, the proliferation of murine pancreatic cancer cell lines was studied following treatment with pregabalin.MethodsSix-week-old pancreatic cancer mouse model KPPC (LSL-KrasG12D/+; Trp53flox/flox; Pdx-1cre/+) was orally administrated pregabalin 30 mg · kg−1 · day−1 (n = 10), or vehicle water (n = 14) until the humane endpoint (no activity, food intake of <1 g · day−1 or more than 20% body weight loss within several days). Cancer-related pain was assessed using the scores of the hunching and mouse grimace scale. Tumor status and plasma cytokine levels were determined using histopathological analysis and cytokine antibody arrays, respectively. Proliferative effect of pregabalin was investigated using mouse pancreatic ductal adenocarcinoma cell lines.ResultsThe number of pancreatic cancer cells were increased by 100 and 300 μM pregabalin in vitro. The pain scores in KPPC mice were decreased by pregabalin, but there was no significant difference in the survival rate or tumor size. Interestingly, pregabalin increased the local infiltration of CD8+ and CD4+ lymphocytes, natural killer cells and CD8+ and CD4+ dendritic cells. In contrast, M2-like tumor-associated macrophages and cancer-associated fibroblasts were reduced. Similar to the results of immuno-inflammatory alterations, plasma cytokines such as tumor necrosis factor-α, interleukin (IL)-6, IL-10, IL-13, CC chemokine ligand (CCL)1, CCL2, CCL3, CCL5 and CCL17 decreased, while IL-2, IL-15, CCL19, CCL21, C-X-C motif ligand (CXCL)10, CXCL16 and XCL1 increased by pregabalin.ConclusionsThese findings suggest that pregabalin increases the proliferative ability of pancreatic cancer cells in vitro without promoting tumor growth in vivo. Additionally, it induces an alteration with an increase in tumor-infiltrating lymphocytes and dendritic cells, along with a decrease in M2-like tumor-associated macrophages and cancer-associated fibroblasts in vivo.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1186/s40360-026-01176-2. Introduction Cancer-related pain is often complex and caused by many factors, including perineuronal invasion, inflammatory and metabolic changes, metastasis and therapeutic side effects [1]. Two-thirds of patients with pancreatic ductal adenocarcinoma (PDAC) have pain in the early stages, while more than 80% have pain in the advanced stage [1]. Appropriate and effective analgesic adjuvants are required for the patients with PDAC to achieve therapeutic insight. Pregabalin (PGB), a non-selective voltage-gated calcium channel α2δ ligand, is widely used as an analgesic for neuropathic cancer-associated pain, including PDAC, across all steps of the World Health Organization analgesic ladder [1]. Indeed, PGB and mirogabalin (MGB), a selective voltage-gated calcium channel α2δ1 and α2δ2 ligand [2, 3], are effective for chemotherapy-induced peripheral neuropathy (CIPN) in patients with PDAC [4]. However, the rate of CIPN improvement is higher in the MGB group compared to the PGB group [4]. The difference in therapeutic effects is attributed to the dissociation half-life time of the α2δ1 subunit (PGB, 1.4 h; MGB, 11.1 h).2 Recently, we found that MGB alleviates cancer-related pain while directly promoting PDAC proliferation and inducing local infiltration of M2-like tumor-associated macrophages (TAMs) in a mouse model with PDAC [5]. In addition, the clinical availability of MGB is mainly concentrated in Asian countries, particularly Japan [6]. Therefore, evaluating the safety of PGB in the context of pancreatic cancer is of broader clinical availability for the global patient population. Here, we hypothesize that PGB, like MGB, can alleviate cancer-related pain while also increasing the risk of progression of PDAC malignancy through changes in microenvironments such as M2-like TAMs. However, the effects of PGB on PDAC and tumor-associated immuno-inflammatory cells are still unknown. In this study, we used a PDAC mouse model (LSL-KrasG12D/+; Trp53flox/flox; Pdx-1cre/+ [KPPC]) with an innate immuno-inflammatory system [7–9] to evaluate the effects of PGB on PDAC and stromal interactions such as tumor-infiltrating lymphocytes (TILs) and dendritic cells (DCs). Methods Reagents and cell lines PGB was purchased from Tokyo Chemical Industry Co., Ltd. (P2840; Tokyo, Japan) for in vitro analysis or Pfizer Pharmaceuticals (Tokyo, Japan) for in vivo analysis, and mirogabalin (MGB) was obtained from Selleck (DS-5565; Tokyo, Japan). These reagents were diluted with distilled water. Murine pancreatic ductal adenocarcinoma (PDAC) cell lines (#146, 147 and 244) were derived from LSL-KrasG12D/+;Trp53flox/+;Pdx-1cre/+ (KPCflox) mice, as described previously [10]. This study was initiated based on previous study showing that mirogabalin can promote pancreatic cancer in mice, so it was tested only in mouse cell lines. Proliferation assay The murine PDAC cell lines (3 × 104 cells) were cultured in 24-well plates with 100 and 300 μM PGB for 48 h, and the number of cells was counted. Meanwhile, the cells (5 × 103 cells) were cultured in 96-well plates with 3, 30 and 300 μM PGB or MGB for 48 h. The absorbance at 490 nm was measured using the manufacturer’s instrument (CellTiter96® Aqueous One Solution Cell Proliferation Assay; Promega, Madison, USA). The experiments were conducted in quadruplicate and repeated three times. Animal model Three individual strains of LSL-KrasG12D/+, Trp53flox/flox, and Pdx-1cre/+ mice were obtained from the Jackson Laboratory (Sacramento, CA). We crossbred the 3 strains to obtain a KPPC (LSL-KrasG12D/+;Trp53flox/flox;Pdx-1cre/+) mouse in our laboratory. KPPC mice were a spontaneous PDAC mouse model under an innate immuno-inflammatory condition [7–9]. When the mice were six weeks old, they were enrolled in the treatment experiment. Administration of PGB to mice KPPC mice were orally administered PGB 30 mg · kg−1 · day−1 (n = 10) every day until the humane endpoint (no activity, food intake of <1 g · day−1 or more than 20% body weight loss within several days). The dosage of PGB (30 mg · kg−1 · day−1) was determined based on previous study demonstrating that oral administration of 30 mg · kg−1 effectively alleviates pain in mice [11]. The experimental endpoint was defined as the time when each mouse reached the humane endpoint. In accordance with 3Rs principles of animal ethics (specifically, “reduction”), and to reduce the number of animals used in experiments, we used data from the vehicle-treated KPPC (n = 14) and healthy control mice (n = 9) [7, 8]. The previous reports were also conducted in the same facility and under the same conditions. All animals were kept in specific pathogen-free housing with abundant food and water before being euthanized using CO2 inhalation at the humane endpoint under institutional guidelines approved by the Animal Care and Use Committee of the School of Medicine, Nihon University (AP21MED012 and AP22MED069) and the Animal Research: Reporting of In Vivo Experiments (ARRIVE). Pain analysis Two blinded investigators evaluated pain signs using the hunching score, which included exploratory behavior (score of 0–4: 0 = normal, 4 = no activity) and the mouse grimace scale (MGS), which included assessment of orbital tightening, nose bulge, cheek bulge, ear position, and whisker change (score of 0–2 each, for a total score of 10) [7–9]. The final scores were determined by averaging the observations from the two investigators. Autopsy All KPPC mice were autopsied at the humane endpoint. The total pancreatic tumor volumes were calculated using the following formula: width × length × height. All samples were weighed and fixed with 10% neutral buffered formalin. Immunohistochemistry Formalin-fixed and paraffin-embedded tissues were immunohistochemically examined, except for dead found mice and tumors with massive central necrosis, as previously described [11]. The antibodies used and the reactive conditions are summarized (Supplementary Table 1). Cases with unclear staining for each internal control were excluded. The number of positive cells in at least three fields (200×) was counted in a representative specimen. DAB substrate (Nichirei, Tokyo, Japan) or HistoGreen/HISTOPRIME® (E109; BIOZOL, Eching, Germany) were used in the development. Cytokine antibody array of the plasma Pooled plasma samples from PGB-treated KPPC mice (n = 6), except for severe icteric and hemolytic samples, were analyzed using a cytokine antibody array (RayBio® C-Series Mouse Cytokine Antibody Array C2000; RayBiotech, Inc., Norcross, GA, USA), as previously described [12]. The data in vehicle KPPC mice (n = 4) and healthy control mice (n = 4) were used from previous reports [7, 8]. The intensity of each cytokine spots was quantified using ImageJ software (National Institutes of Health, USA), background signals were subtracted, and the intensity was normalized to a positive control spots on each membrane. Statistical analysis The significance of the proliferation of PDAC cell lines was determined using the Tukey multiple comparison test after a one-way analysis of variance. The significant differences in cancer-related pain were determined using the Mann–Whitney U-test. Log-rank test for univariate survival analyses was used to determine the difference in survival ratio in the Kaplan–Meier curves. Tumor volumes and histopathological analyses were performed by parametric Student’s t-test or the non-parametric Mann–Whitney U-test with EZR (Easy R), version 2.71 [13. ]p-values less than 0.05 were used to determine statistical significance. Results PGB enhanced the proliferative potential of PDAC in vitro, but the effects of PGB were weaker than that of MGB To determine the direct proliferative effect of PGB on PDAC cells, we examined the proliferative potentials of murine PDAC cell lines (#146, 147, 244) in the presence of PGB in vitro. As expected, the number of PDAC cells increased by exposure to PGB in a dose-dependent manner (Fig. 1a). Especially, 300-μM PGB significantly enhanced the proliferative potential of PADC cells compared to the vehicle (#146: 34.9 vs 14.4 × 104 cells, p < 0.001, #147: 34.9 vs 23.8 × 104 cells, p = 0.003, #244: 9.6 vs 4.3 × 104 cells, p = 0.002). Next, we examined the proliferative ability of PDAC cell lines in the presence of the same concentrations of PGB and MGB to determine the functional difference of the reagents to PDAC cells (Fig. 1b). Interestingly, PBG had a weaker effect on the proliferative potentials of PDAC cells than that MGB at all concentrations (3, 30 and 300 μM). For instance, at 300 μM, the absorbance (490 nm) in PGB was notably lower than that in MGB in both #146 (p = 0.003) and #147 (p = 0.005).Fig. 1Increased PDAC proliferation caused by PGB in vitro. (a) The number of murine PDAC cell lines (#146, 147, 244) treated with PGB 100 and 300 μM for 48 h. The data is in quadruplicate. #146 (mean [standard error (SE)]); p = 0.024, 95% CI [15840.20– 198,159.80], 100-μM PGB vs. vehicle (n = 4 each); p < 0.001, 95% CI [114090.20– 296,409.80], 300-μM PGB vs. vehicle (n = 4 each); p = 0.036, 95% CI [7090.20– 189,409.80], 100-μM PGB vs. 300-μM PGB (n = 4 each) by the Tukey multiple comparison test after one-way analysis of variance. #147 (mean [SE]); p = 0.441, 95% CI [−35525.44 to 95,525.44], 100-μM PGB vs. vehicle (n = 4 each); p = 0.003, 95% CI [45474.56– 176,525.44], 300-μM PGB vs. vehicle (n = 4 each); p = 0.018, 95% CI [15474.56– 146,525.44], 100-μM PGB vs. 300-μM PGB (n = 4 each) by the Tukey multiple comparison test after one-way analysis of variance. #244 (mean [SE]); p = 0.022, 95% CI [5474.28– 62,474.72], 100-μM PGB vs. vehicle (n = 4 each); p = 0.002, 95% CI [23825.28– 80,824.72], 300-μM PGB vs. vehicle (n = 4 each); p = 0.225, 95% CI [−10149.72 to 46,849.72], 100-μM PGB vs. 300-μM PGB (n = 4 each) using the Tukey multiple comparison test after one-way analysis of variance. (b) The absorbance (490 nm) of murine PDAC cell lines (#146, 147) in the presence of PGB 3, 30 and 300 μM (P3, P30, P300) and that of MGB 3, 30 and 300 μM (M3, M30, M300) for 48 h. The data is in quadruplicate. #146 (mean [SE]); p = 0.030, 95% CI [0.02–0.31], P3 vs. M3 (n = 4 each); p = 0.060, 95% CI [−0.01 to 0.43], P30 vs. M30 (n = 4 each); p = 0.003, 95% CI [0.23–0.68], P300 vs. M300 (n = 4 each) by parametric Student’s t-test. #147 (mean [SE]); p < 0.001, 95% CI [0.17–0.32], P3 vs. M3 (n = 4 each); p = 0.003, 95% CI [0.18–0.53], P30 vs. M30 (n = 4 each); p = 0.005, 95% CI [0.16–0.56], P300 vs. M300 (n = 4 each) by parametric Student’s t-test. CI, confidence interval; PDAC, pancreatic ductal adenocarcinoma; PGB, pregabalin; MGB, mirogabalin; SE, standard error Increased PDAC proliferation caused by PGB in vitro. (a) The number of murine PDAC cell lines (#146, 147, 244) treated with PGB 100 and 300 μM for 48 h. The data is in quadruplicate. #146 (mean [standard error (SE)]); p = 0.024, 95% CI [15840.20– 198,159.80], 100-μM PGB vs. vehicle (n = 4 each); p < 0.001, 95% CI [114090.20– 296,409.80], 300-μM PGB vs. vehicle (n = 4 each); p = 0.036, 95% CI [7090.20– 189,409.80], 100-μM PGB vs. 300-μM PGB (n = 4 each) by the Tukey multiple comparison test after one-way analysis of variance. #147 (mean [SE]); p = 0.441, 95% CI [−35525.44 to 95,525.44], 100-μM PGB vs. vehicle (n = 4 each); p = 0.003, 95% CI [45474.56– 176,525.44], 300-μM PGB vs. vehicle (n = 4 each); p = 0.018, 95% CI [15474.56– 146,525.44], 100-μM PGB vs. 300-μM PGB (n = 4 each) by the Tukey multiple comparison test after one-way analysis of variance. #244 (mean [SE]); p = 0.022, 95% CI [5474.28– 62,474.72], 100-μM PGB vs. vehicle (n = 4 each); p = 0.002, 95% CI [23825.28– 80,824.72], 300-μM PGB vs. vehicle (n = 4 each); p = 0.225, 95% CI [−10149.72 to 46,849.72], 100-μM PGB vs. 300-μM PGB (n = 4 each) using the Tukey multiple comparison test after one-way analysis of variance. (b) The absorbance (490 nm) of murine PDAC cell lines (#146, 147) in the presence of PGB 3, 30 and 300 μM (P3, P30, P300) and that of MGB 3, 30 and 300 μM (M3, M30, M300) for 48 h. The data is in quadruplicate. #146 (mean [SE]); p = 0.030, 95% CI [0.02–0.31], P3 vs. M3 (n = 4 each); p = 0.060, 95% CI [−0.01 to 0.43], P30 vs. M30 (n = 4 each); p = 0.003, 95% CI [0.23–0.68], P300 vs. M300 (n = 4 each) by parametric Student’s t-test. #147 (mean [SE]); p < 0.001, 95% CI [0.17–0.32], P3 vs. M3 (n = 4 each); p = 0.003, 95% CI [0.18–0.53], P30 vs. M30 (n = 4 each); p = 0.005, 95% CI [0.16–0.56], P300 vs. M300 (n = 4 each) by parametric Student’s t-test. CI, confidence interval; PDAC, pancreatic ductal adenocarcinoma; PGB, pregabalin; MGB, mirogabalin; SE, standard error PGB improved cancer-associated pain in mice with PDAC We then confirmed the analgesic effects of PGB on our PDAC mouse model KPPC, as PGB is effective for neuropathic pain in cancer patients [14]. Six-week-old KPPC mice were orally administered 30 mg · kg−1 · day−1 PGB (Fig. 2a). Vehicle-treated KPPC mice demonstrated signs of pain, including a severe rounded-back posture (Fig. 2b), whereas PGB inhibited the signs of pain, including a mild rounded-back posture (Fig. 2b). In healthy mice, no signs of pain were observed in mice treated with PGB or vehicle (Supplementary Fig. 1). Hunching scores decreased after PGB treatment in 44–64 day old KPPC mice compared to vehicle-treated mice (Fig. 2c; Supplementary Fig. 2a). Similar to the results of hunching, MGS scores improved from 54 to 64 days old in PGB-treated KPPC mice when compared to vehicle-treated KPPC mice (Fig. 2d; Supplementary Fig. 2b). Meanwhile, there was no significant difference in survival rates between PGB-treated mice (median survival time of 62 days) and vehicle-treated KPPC mice (62 days) (Supplementary Fig. 3). Furthermore, solid and whitish pancreatic nodules were found in both KPPC mice groups (Fig. 2e), but there was no significant difference in pancreatic weight or tumor size between the two groups (Fig. 2f). Furthermore, there was no significant difference in the frequency of direct invasion to another tissue/organ or distant metastasis/dissemination between the two groups (Supplementary Tables 3 and 4).Fig. 2PGB reduced cancer-related pain significantly while not affecting the growth of PDAC in vivo. (a) Experimental design. The arrows indicate administration of pregabalin. (b) Vehicle-treated LSL-KrasG12D/+;Trp53flox/flox;Pdx-1cre/+ (KPPC) mice showing pain symptoms including a severe rounded-back posture (hunching score 4), nose, and cheek bulge (MGS 9). PGB improves pain symptoms (hunching score 1 and MGS 2). (c) Cumulative scores for hunching and (d) MGS (median) in KPPC mice treated with PGB (n = 10) and vehicle water (n = 11). *, p < 0.05 by non-parametric Mann–Whitney U-test. (e) Gross appearance of a pancreatic tumor (arrows). Du means duodenum. (f) Weight of the whole pancreas (mean [SD]) and tumor volume (mean [SD]) in KPPC mice treated with PGB or vehicle water. Weight; p = 0.341, 95% CI [−608.00 to 219.50], PGB (n = 10) vs. vehicle (n = 14) by parametric Student’s t-test. Volume; p = 0.423, 95% CI [−585.18 to 254.44], PGB (n = 10) vs. vehicle (n = 14) by Student’s t-test. MGS is the mouse grimace scale; PGB is pregabalin; and SD is the standard deviation PGB reduced cancer-related pain significantly while not affecting the growth of PDAC in vivo. (a) Experimental design. The arrows indicate administration of pregabalin. (b) Vehicle-treated LSL-KrasG12D/+;Trp53flox/flox;Pdx-1cre/+ (KPPC) mice showing pain symptoms including a severe rounded-back posture (hunching score 4), nose, and cheek bulge (MGS 9). PGB improves pain symptoms (hunching score 1 and MGS 2). (c) Cumulative scores for hunching and (d) MGS (median) in KPPC mice treated with PGB (n = 10) and vehicle water (n = 11). *, p < 0.05 by non-parametric Mann–Whitney U-test. (e) Gross appearance of a pancreatic tumor (arrows). Du means duodenum. (f) Weight of the whole pancreas (mean [SD]) and tumor volume (mean [SD]) in KPPC mice treated with PGB or vehicle water. Weight; p = 0.341, 95% CI [−608.00 to 219.50], PGB (n = 10) vs. vehicle (n = 14) by parametric Student’s t-test. Volume; p = 0.423, 95% CI [−585.18 to 254.44], PGB (n = 10) vs. vehicle (n = 14) by Student’s t-test. MGS is the mouse grimace scale; PGB is pregabalin; and SD is the standard deviation PGB altered tumor microenvironments and enhanced recruitment of TILs and DCs To answer the question of why PGB increased the proliferative potential of PDAC in vitro but did not affect the tumor size in vivo, we histopathologically compared tumors in KPPC mice treated with/without PGB (Supplementary Table 2). There was no significant difference in the proliferative Ki-67 indexes in epithelial cytokeratin 19 (K19)+ PDAC between PGB-treated KPPC mice (23.7%) and vehicle-treated mice (32.6%) (Fig. 3a and b). Meanwhile, the number of α-smooth muscle actin (α-SMA)+ cancer-associated fibroblasts (CAFs) decreased in PGB-treated mice compared to those in vehicle-treated mice (Fig. 3a and b). The number of CD31+ tumor blood vessels remained unchanged, while microvessel patency was preserved in mice treated with PGB (Fig. 3a and b).Fig. 3PGB enhanced tumor microenvironments, including CAFs, tumor vessel patency and local immuno-inflammatory cell infiltration. (a) Representative histological features of PDAC in mice treated with PGB or vehicle (200×). Immunohistochemical-positive cells were identified using DAB (brown) or HistGreen (green). The nuclear staining was done with hematoxylin (purple). Insets, 400× original magnification. Scale bars, 100 μm. (b) Quantification of the staining in (a). Ki-67 (mean [SD]); p = 0.121, 95% CI [−20.58 to 2.75], PGB (n = 6) vs. vehicle (n = 7) by Student’s t-test. α-SMA (median); p = 0.002, PGB (n = 6) vs. vehicle (n = 6) by Mann–Whitney U-test. The number of CD31 (mean [SD]); p = 0.691, 95% CI [−28.53 to 19.77], PGB (n = 6) vs. vehicle (n = 5) using Student’s t-test. Area of CD31 (mean [SD]); p < 0.001, 95% CI [0.39–1.07], PGB (n = 6) vs. vehicle (n = 5) by Student’s t-test. MPO (median), p = 0.128, PGB (n = 5) vs. vehicle (n = 7) by the Mann–Whitney U-test. iNOS (mean [SD]); p = 0.444, 95% CI [−82.61 to 175.71], PGB (n = 6) vs. vehicle (n = 7) by Student’s t-test. Arginase-1 (mean [SD]); p < 0.001, 95% CI [−1379.80 to −494.69], PGB (n = 6) vs. vehicle (n = 9) by Student’s t-test. NK1.1 (median); p = 0.039, PGB (n = 6) vs. vehicle (n = 5) by the Mann–Whitney U-test. α-SMA stands for α-smooth muscle actin; CAF stands for cancer-associated fibroblast and CI represents a confidence interval. DAB stands for 3, 3’-diaminobenzidine; HE is hematoxylin and eosin; iNOS is inducible nitric oxide synthase; K19 is cytokeratin 19; MPO is myeloperoxidase; NK is natural killer; PGB is pregabalin; and SD is standard deviation PGB enhanced tumor microenvironments, including CAFs, tumor vessel patency and local immuno-inflammatory cell infiltration. (a) Representative histological features of PDAC in mice treated with PGB or vehicle (200×). Immunohistochemical-positive cells were identified using DAB (brown) or HistGreen (green). The nuclear staining was done with hematoxylin (purple). Insets, 400× original magnification. Scale bars, 100 μm. (b) Quantification of the staining in (a). Ki-67 (mean [SD]); p = 0.121, 95% CI [−20.58 to 2.75], PGB (n = 6) vs. vehicle (n = 7) by Student’s t-test. α-SMA (median); p = 0.002, PGB (n = 6) vs. vehicle (n = 6) by Mann–Whitney U-test. The number of CD31 (mean [SD]); p = 0.691, 95% CI [−28.53 to 19.77], PGB (n = 6) vs. vehicle (n = 5) using Student’s t-test. Area of CD31 (mean [SD]); p < 0.001, 95% CI [0.39–1.07], PGB (n = 6) vs. vehicle (n = 5) by Student’s t-test. MPO (median), p = 0.128, PGB (n = 5) vs. vehicle (n = 7) by the Mann–Whitney U-test. iNOS (mean [SD]); p = 0.444, 95% CI [−82.61 to 175.71], PGB (n = 6) vs. vehicle (n = 7) by Student’s t-test. Arginase-1 (mean [SD]); p < 0.001, 95% CI [−1379.80 to −494.69], PGB (n = 6) vs. vehicle (n = 9) by Student’s t-test. NK1.1 (median); p = 0.039, PGB (n = 6) vs. vehicle (n = 5) by the Mann–Whitney U-test. α-SMA stands for α-smooth muscle actin; CAF stands for cancer-associated fibroblast and CI represents a confidence interval. DAB stands for 3, 3’-diaminobenzidine; HE is hematoxylin and eosin; iNOS is inducible nitric oxide synthase; K19 is cytokeratin 19; MPO is myeloperoxidase; NK is natural killer; PGB is pregabalin; and SD is standard deviation We next investigated the effects of PGB on local immuno-inflammatory cell infiltration. Proinflammatory myeloperoxidase+ tumor-associated neutrophils [15] and inducible nitric oxide synthase+ antitumor M1-like TAMs were not altered by PGB (Fig. 3a and b). Meanwhile, arginase-1+ tumor-promoting M2-like TAMs [15] decreased after PGB treatment (Fig. 3a and b). In contrast, NK1.1-positive natural killer (NK) cells increased in PGB-treated mice (Fig. 3a and b). The local infiltration of CD8+ dendritic cells (DCs), which are double-positive cells for CD8 and major histocompatibility complex (MHC) class II and are estimated as conventional DC1 (cDC1) [16], increased by administration of PGB (Fig. 4a and b). Also, double-positive cells for CD4 and MHC class II, known as cDC2 [16], increased in mice treated with PGB (Fig. 4a and b). Moreover, local cytotoxic CD8–single positive lymphocytes and helper CD4–single positive lymphocytes increased in mice treated with PGB (Fig. 4a and b). A few local CD45R+ B cells were discovered in the pancreatic tumor of PGB- and vehicle-treated mice (Supplementary Figs. 4). Meanwhile, the number of CD8+ DCs, but not CD4+ DCs, in pancreatic lymph nodes increased in mice with PGB than in vehicle-treated mice (Fig. 4a and b).Fig. 4PGB increased the local infiltration of CD8+ DCs and CD4+ DCs as well as CD8+ and CD4+ lymphocytes. (a) CD8 and CD4 (brown) and MHC class II (green) in PDAC and pancreatic lymph nodes were detected in KPPC mice treated with/without PGB (200×). Insets show double-positive DCs with 400× original magnification. Scale bars: 100 μm. (b) Quantification of the staining in (a). Local CD8+ DCs (mean [SD]); p = 0.004, 95% CI [40.35–153.08], PGB (n = 6) vs. vehicle (n = 5) using Student’s t-test. Local CD4+ DCs (median); p = 0.006, PGB (n = 6) vs. vehicle (n = 6) by the Mann–Whitney U-test. Local CD8 (mean [SD]); p = 0.029, 95% CI [11.26–169.01], PGB (n = 6) vs. vehicle (n = 5) by Student’s t-test. Local CD4 (median); p = 0.010, PGB (n = 6) vs. vehicle (n = 6) by the Mann–Whitney U-test. CD8+ DCs in LN (median); p = 0.004, PGB (n = 6) vs. vehicle (n = 5) by the Mann–Whitney U-test. CD4+ DCs in LN (median); p = 0.476, PGB (n = 6) vs. vehicle (n = 6) by the Mann–Whitney U-test. CI indicates confidence interval, DC indicates dendritic cell, MHC indicates major histocompatibility complex, LN indicates lymph node, PDAC indicates pancreatic ductal adenocarcinoma, PGB indicates pregabalin and SD indicates standard deviation PGB increased the local infiltration of CD8+ DCs and CD4+ DCs as well as CD8+ and CD4+ lymphocytes. (a) CD8 and CD4 (brown) and MHC class II (green) in PDAC and pancreatic lymph nodes were detected in KPPC mice treated with/without PGB (200×). Insets show double-positive DCs with 400× original magnification. Scale bars: 100 μm. (b) Quantification of the staining in (a). Local CD8+ DCs (mean [SD]); p = 0.004, 95% CI [40.35–153.08], PGB (n = 6) vs. vehicle (n = 5) using Student’s t-test. Local CD4+ DCs (median); p = 0.006, PGB (n = 6) vs. vehicle (n = 6) by the Mann–Whitney U-test. Local CD8 (mean [SD]); p = 0.029, 95% CI [11.26–169.01], PGB (n = 6) vs. vehicle (n = 5) by Student’s t-test. Local CD4 (median); p = 0.010, PGB (n = 6) vs. vehicle (n = 6) by the Mann–Whitney U-test. CD8+ DCs in LN (median); p = 0.004, PGB (n = 6) vs. vehicle (n = 5) by the Mann–Whitney U-test. CD4+ DCs in LN (median); p = 0.476, PGB (n = 6) vs. vehicle (n = 6) by the Mann–Whitney U-test. CI indicates confidence interval, DC indicates dendritic cell, MHC indicates major histocompatibility complex, LN indicates lymph node, PDAC indicates pancreatic ductal adenocarcinoma, PGB indicates pregabalin and SD indicates standard deviation Plasma cytokine levels were altered in mice with administration of PGB We measured the pooled plasma cytokine levels using a cytokine antibody array to better understand the systemic pathogenesis in PGB-treated PDAC mice (Fig. 5, Supplementary Figs. 5, 6, 7, 8, 9, 10, Table 1). Interestingly, major nociceptive pain-associated cytokines including tumor necrosis factor-alpha (TNF-α), interleukin (IL)-1β and IL-6 reduced in PGB-treated mice compared with those in vehicle-treated mice. Indeed, IL-10, IL-13, CC chemokine ligands (CCLs) (i.e. CCL1, CCL3, CCL5, CCL17 and CCL22), stem cell factor (SCF) and macrophage colony-stimulating factor (M-CSF) reduced in PGB-treated mice. In contrast, IL-2, IL-15, CCL19, CCL21, CXCL16 and XCL1 increased in PGB-treated mice.Fig. 5PGB affected plasma cytokine levels in mice. Pooled plasma cytokine levels in normal control (N, n = 4), KPPC mice given vehicle water (V, n = 4), and PGB administration (P, n = 6). The data are presented as the means of two array spots. CCL, CC chemokine ligand; CXCL, C-X-C motif ligand; IFN-γ, interferon-γ; IL, interleukin; M-CSF, macrophage colony-stimulating factor; PGB, pregabalin; SCF, stem cell factor; TNF, tumor necrosis factor; XCL, X-C motif chemokine ligandTable 1Main plasma cytokines affected by PGB in miceExpression PatternCytokine NamesCytokines with Increase (Fold change > 1.5)IL-2, IL-15, CCL19, CCL21, CXCL10, CXCL16, XCL1Cytokines with Decrease (Fold change < 0.6)TNF-α, IL-1β, IL-6, IL-10, IL-13, CCL1, CCL3, CCL5, CCL17, CCL22, SCF, G-CSF, M-CSFPlasma cytokine levels were analyzed in KPPC mice to identify profiles altered by PGB administration. Thresholds for meaningful changes were set at a fold change of > 1.5 for increased cytokines and < 0.6 for decreased cytokines. CCL, CC chemokine ligand; CXCL, C-X-C motif ligand; IFN-γ, interferon-γ; IL, interleukin; M-CSF, macrophage colony-stimulating factor; PGB, pregabalin; SCF, stem cell factor; TNF, tumor necrosis factor; XCL, X-C motif chemokine ligand PGB affected plasma cytokine levels in mice. Pooled plasma cytokine levels in normal control (N, n = 4), KPPC mice given vehicle water (V, n = 4), and PGB administration (P, n = 6). The data are presented as the means of two array spots. CCL, CC chemokine ligand; CXCL, C-X-C motif ligand; IFN-γ, interferon-γ; IL, interleukin; M-CSF, macrophage colony-stimulating factor; PGB, pregabalin; SCF, stem cell factor; TNF, tumor necrosis factor; XCL, X-C motif chemokine ligand Table 1Main plasma cytokines affected by PGB in miceExpression PatternCytokine NamesCytokines with Increase (Fold change > 1.5)IL-2, IL-15, CCL19, CCL21, CXCL10, CXCL16, XCL1Cytokines with Decrease (Fold change < 0.6)TNF-α, IL-1β, IL-6, IL-10, IL-13, CCL1, CCL3, CCL5, CCL17, CCL22, SCF, G-CSF, M-CSFPlasma cytokine levels were analyzed in KPPC mice to identify profiles altered by PGB administration. Thresholds for meaningful changes were set at a fold change of > 1.5 for increased cytokines and < 0.6 for decreased cytokines. CCL, CC chemokine ligand; CXCL, C-X-C motif ligand; IFN-γ, interferon-γ; IL, interleukin; M-CSF, macrophage colony-stimulating factor; PGB, pregabalin; SCF, stem cell factor; TNF, tumor necrosis factor; XCL, X-C motif chemokine ligand Main plasma cytokines affected by PGB in mice Plasma cytokine levels were analyzed in KPPC mice to identify profiles altered by PGB administration. Thresholds for meaningful changes were set at a fold change of > 1.5 for increased cytokines and < 0.6 for decreased cytokines. CCL, CC chemokine ligand; CXCL, C-X-C motif ligand; IFN-γ, interferon-γ; IL, interleukin; M-CSF, macrophage colony-stimulating factor; PGB, pregabalin; SCF, stem cell factor; TNF, tumor necrosis factor; XCL, X-C motif chemokine ligand Discussion In this study, we found that PGB may be able to improve cancer-associated pain by altering inflammatory cytokines in a PDAC mouse model. Inflammatory cytokines, which are secreted not only by stromal inflammatory cells but also by PDAC and CAF [10], promote inflammatory nociceptive pain [1]. According to a previous study, PGB blocks lipopolysaccharide (LPS)/concanavalin A-induced IL-6 and TNF-α secretion in splenocytes and LPS-induced IL-1β secretion, but not peripheral macrophages in vivo [17]. However, our results and previous reports indicate that the decrease in TNF-α, IL-1β, IL-6, CCL1 and CCL5 could be due to inhibition of CAFs or M2-like TAMs (Fig. 6) [12, 18]. CCL3 and M-CSF levels may be reduced by inhibiting CAF-associated cytokines [19, 20]. whereas IL-10, IL-13, CCL17 and CCL22 levels may be reduced by inhibiting M2-like TAMs [21] Therefore, PGB may inhibit both neuropathic and nociceptive pain by reducing inflammatory cytokines.Fig. 6Hypothetical effects of PGB on cancer-stromal microenvironments, including the role of plasma cytokine levels. (a) PGB inhibited CAFs, maintained microvessel patency and increased the infiltration of local TILs (CD4+ lymphocytes, CD8+ lymphocytes, NK cells) and DCs. (b) CAF-related cytokines decreased, including TNF-α, IL-6, CCL1, CCL3 and CCL5). M2-like TAM related cytokines decreased (IL-6, IL-13, CCL1, CCL5, CCL17 and CCL22). Low levels of IL-1β, SCF, M-CSF and G-CSF can inhibit the differentiation of macrophages. Reduced IL-10 levels may promote the recruitment of TILs. DCs may induce the recruitment of TILs (i.e. IL-15, CCL19, CXCL10 and CXCL16), whereas a high level of XCL1 may recruit local DCs. Increased IL-2 and XCL1 levels may activate TILs themselves. Solid lines represent reactions to previous reports and current data. Dotted lines represent predicted reactions. α-SMA stands for α-smooth muscle, CCL for CC chemokine ligand, CXCL for C-X-C motif ligand and CAF for cancer-associated fibroblast. DC is dendritic cell; IFN is interferon; IL is interleukin; K19 is cytokeratin 19; M-CSF is macrophage colony-stimulating factor; MPO is myeloperoxidase; and NK is natural killer. PDAC stands for pancreatic ductal adenocarcinoma; PGB is pregabalin; and SCF is a stem cell factor. TAM stands for tumor-associated macrophage; TILs are tumor-infiltrating lymphocytes; TNF is tumor necrosis factor; and XCL is X-C motif chemokine ligand Hypothetical effects of PGB on cancer-stromal microenvironments, including the role of plasma cytokine levels. (a) PGB inhibited CAFs, maintained microvessel patency and increased the infiltration of local TILs (CD4+ lymphocytes, CD8+ lymphocytes, NK cells) and DCs. (b) CAF-related cytokines decreased, including TNF-α, IL-6, CCL1, CCL3 and CCL5). M2-like TAM related cytokines decreased (IL-6, IL-13, CCL1, CCL5, CCL17 and CCL22). Low levels of IL-1β, SCF, M-CSF and G-CSF can inhibit the differentiation of macrophages. Reduced IL-10 levels may promote the recruitment of TILs. DCs may induce the recruitment of TILs (i.e. IL-15, CCL19, CXCL10 and CXCL16), whereas a high level of XCL1 may recruit local DCs. Increased IL-2 and XCL1 levels may activate TILs themselves. Solid lines represent reactions to previous reports and current data. Dotted lines represent predicted reactions. α-SMA stands for α-smooth muscle, CCL for CC chemokine ligand, CXCL for C-X-C motif ligand and CAF for cancer-associated fibroblast. DC is dendritic cell; IFN is interferon; IL is interleukin; K19 is cytokeratin 19; M-CSF is macrophage colony-stimulating factor; MPO is myeloperoxidase; and NK is natural killer. PDAC stands for pancreatic ductal adenocarcinoma; PGB is pregabalin; and SCF is a stem cell factor. TAM stands for tumor-associated macrophage; TILs are tumor-infiltrating lymphocytes; TNF is tumor necrosis factor; and XCL is X-C motif chemokine ligand A recent study found that gabapentinoids, such as PGB, MGB and gabapentin (GPN) interact with α2δ1 of neuronal cells in spinal dorsal horn and alleviate neuropathic pain by activating the descending noradrenergic inhibitory system [22]. PGB and GPN react with astroglia glutamate transporter-1 (GLT-1) in the locus coeruleus, releasing glutamate and activating the descending noradrenergic inhibitory system [23, 24]. A decrease in pain mediators such as CCL2, CCL3 and CCL5 in the spinal cord and peripheral nervous system reduces pain symptoms [25, 26]. Therefore, PGB may also alleviate cancer- related pain via α2δ units in the dorsal horn, GLT-1 in the locus coeruleus or reduced CCLs. According to our recent findings, MGB alleviates cancer-related pain while promoting tumor growth in vitro and in vivo [5]. Similar to the results of MGB, PGB improved cancer-associated pain while increasing PDAC’s proliferative potential in vitro. The expression of α2δ1 subunit, a binding receptor for MGB and PGB, is a cancer-stem-like marker in several cancers, including lung [27], liver [28], and gastric cancers [29]. The α2δ1 high-expressed group in patients with bladder and ovarian cancers reveals a poor prognosis compared to those with α2δ1 low-expressed group [30, 31], indicating that reaction with α2δ1 may increase the malignant potential of PDAC. Interestingly, PGB has a shorter dissociation time from α2δ1 than MGB [2]. Our results show that the proliferative ability of PDAC by PGB was lower than the effects of the same concentration of MGB. Therefore, the short reaction of PGB with the α2δ1 subunit may explain why it has a lower potential to promote PDAC proliferation. The alteration of tumor-stromal microenvironments by PGB might be closely related to the fact that PGB did not promote tumor growth in vivo. In this study, we found that PGB increased the local increase of anti-tumor TILs and DCs. A recent study found that CD4+ lymphocytes increase with PGB treatment in patients with postherpetic neuralgia [32]. The increase in TILs could be attributed to stimulation of the recruitment with high cytokine levels such as IL-15, CCL19, CCL21, CXCL10 and CXCL16 [33, 34]; decrease in IL-10 [35], decrease in CAFs and retention of vascular patency [36]. XCL1 secreted from TILs stimulates the recruitment of DCs, whereas IL-15, CCL19, CXCL10 and CXCL16, which might be derived from DCs may induce proliferation and activation of TILs [34, 37, 38]. Increased IL-2 and XCL1 secretion by TILs may also stimulate themselves [34, 38]. A decrease in CAF-derived IL-1β and M-CSF may hinder the differentiation of M2-like TAMs [19, 20]. A decrease in CAFs maintains vascular patency and may encourage the recruitment of local CTLs and DCs [39]. cDC1 presents tumor antigens to CD8+ lymphocytes, promoting cytotoxicity T cell immunity, whereas cDC2 presents tumor antigens to CD4+ T lymphocytes, promoting helper T cell-associated immune responses [16]. Therefore, despite increasing PDAC proliferation in vitro, PGB did not promote tumor growth in vivo, which was accompanied by an increase in TILs and DCs and a decrease in M2-like TAMs and CAFs. These microenvironmental alterations may play a critical role in vivo against PGB-induced tumor progression. These effects of PGB would be important in PDAC patients when considering therapeutic options, particularly immunotherapy. Long-term administration of PGB for 12 months causes hemangiosarcoma in a mouse model [40]. However, because KPPC mice die at around 70 days old, we could not evaluate the long-term administration of PGB using the KPPC model, which is a limitation of this study. Plasma cytokine levels vary according to not only the status of PDAC and immuno-inflammatory cells but also stroma such as CAF [19]; thus, the origin of cytokines cannot be determined precisely. While our findings describe the effects of PGB on the tumor microenvironment in an immunocompetent host, further experiments using nude mice and isolated CD4+ and CD8+ T cells are needed to further explore the direct mechanisms of PGB. A recent clinical study found that MGB improves CIPN more effectively than PGB in patients with PDAC [4]. However, our findings suggest that PGB would be a safer analgesic in patients with PDAC. Since this study was conducted exclusively in a murine model, future investigations, including in vitro experiments using human pancreatic cancer cell lines and retrospective clinical studies of human tissue samples, are necessary to validate the translatability and clinical relevance of these findings. In conclusion, PGB increases the proliferative potential of PDAC in vitro, but in vivo it improves cancer-associated pain without promoting tumor growth. Additionally, it induces alterations in tumor microenvironments with an increase in TILs and DCs and a decrease in M2-like TAMs and CAFs. Electronic supplementary material Below is the link to the electronic supplementary material. Supplementary material 1 Supplementary material 1